ANNEXA (TM)-R Part 2: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Sustained Reversal of Rivaroxaban-Induced Anticoagulation in Older Subjects by Andexanet Alfa (PRT064445), a Universal Antidote for Factor XA (FXA) Inhibitors Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Crowther, Mark
  • Gold, Alex
  • Lu, Genmin
  • Leeds, Janet M
  • Wiens, Brian L
  • Marthur, Vandana
  • Castillo, Janice
  • Conley, Pamela B
  • Connolly, Stuart
  • Curnutte, John T

publication date

  • December 8, 2015